PD-1/PD-L1
PD-1/PD-L1 inhibitors are immune checkpoint inhibitors that block the interaction between the programmed cell death protein 1 (PD-1) on T cells and its ligand PD-L1 on cancer cells. This interaction normally suppresses the immune response and allows cancer cells to evade immune detection. By inhibiting PD-1/PD-L1, these inhibitors enhance the immune system's ability to recognize and destroy cancer cells, inducing apoptosis and tumor regression. PD-1/PD-L1 inhibitors are critical in immunotherapy research and cancer treatment. At CymitQuimica, we offer a range of high-quality PD-1/PD-L1 inhibitors to support your research in immuno-oncology, apoptosis, and cancer therapy.
Found 125 products of "PD-1/PD-L1"
Sort by
Purity (%)
0
100
|
0
|
50
|
90
|
95
|
100
AUNP-12 acetate
<p>AUNP-12 acetate is a polypeptide inhibitor of PD-1 that is equivalent to PD-1 and PD-2 in inhibiting lymphocyte proliferation and effector fuction, in addition</p>Formula:C144H230N40O50Purity:95.07%Color and Shape:SolidMolecular weight:3321.61Durvalumab
CAS:<p>Durvalumab is a humanized antibody for cancer, inhibiting PD-L1/PD-1 and CD80 interactions at very low concentrations.</p>Purity:SDS-PAGE:97.2%;SEC-HPLC:95.3%Color and Shape:LiquidMolecular weight:146.03 kDaEzabenlimab
CAS:<p>Ezabenlimab (BI-754091) is an anti-PD-1 mAb, Kd 6 nM, blocks PD-1/PD-Ls, boosts T-cell IFN-γ, inhibits tumors in vivo.</p>Purity:99.1% (SDS-PAGE); 96.9% (SEC-HPLC) - 99.1% (SDS-PAGE); 96.9% (SEC-HPLC)Color and Shape:LiquidBudigalimab
CAS:<p>Budigalimab (ABBV 181) is a humanized monoclonal antibody targeting PD-1 with potential antitumor activity.</p>Purity:97% (SDS-PAGE); 98.8% (SEC-HPLC) - 97% (SDS-PAGE); 98.8% (SEC-HPLC)Color and Shape:LiquidSintilimab
CAS:<p>Sintilimab (IBI308), an IgG4 monoclonal antibody, blocks PD-1, enhancing T-cell anti-tumor response; treats Hodgkin's, lung, and esophageal cancers.</p>Purity:> 95%Color and Shape:LiquidMolecular weight:144.04 kDaZimberelimab
CAS:<p>Zimberelimab (GLS-010) is a humanized antibody targeting PD-1, with anticancer activity.</p>Purity:95%Color and Shape:LiquidTislelizumab
CAS:<p>Tislelizumab, a PD-1 receptor monoclonal antibody, reduces Fcγ interaction and T cell clearance in advanced squamous NSCLC research.</p>Purity:95.07%Color and Shape:LiquidPenpulimab
CAS:<p>Penpulimab is a monoclonal antibody targeting PD-1 with antitumor activity, used in studies of pancreatic cancer.</p>Purity:96.8% (SEC-HPLC) - 96.8% (SEC-HPLC)Color and Shape:LiquidSpartalizumab
CAS:<p>"Spartalizumab (PDR001), a humanized IgG4 monoclonal antibody, targets PD-1 to inhibit PD-L1/L2 interactions, useful in ATC research."</p>Purity:SDS-PAGE:95.2%;SEC-HPLC:96.3%Color and Shape:LiquidMolecular weight:145.74 kDaBMS-1001 hydrochloride
CAS:<p>BMS-1001 hydrochloride is an orally active inhibitor of human PD-1/PD-L1 immune checkpoint with low-toxicity in cells.BMS-1001 alleviates the inhibitory effect</p>Formula:C35H35ClN2O7Purity:97.36%Color and Shape:SolidMolecular weight:631.11Dostarlimab
CAS:<p>Dostarlimab (TSR-042) is an immune checkpoint inhibitor targeting PD-1, blocking its interaction with its ligands PD-L1 and PD-L2.</p>Purity:>95%Color and Shape:LiquidEciskafusp alfa
CAS:<p>Eciskafusp alfa, a cis-targeted IL2v immunocytokine, acts on programmed cell death 1 (PDCD1, commonly known as PD-1), preferentially targeting antigen-specific</p>Purity:98%Color and Shape:SolidPM-8002
<p>PM-8002 is a bispecific antibody that targets PD-L1 and VEGF-A. It is applicable for research on solid tumors.</p>Color and Shape:Odour LiquidAnti-Mouse PD-1 (LALA-PG) Antibody (RMP1-14)
<p>Anti-MousePD-1(LALA-PG) Antibody (RMP1-14) is an IgG2a, κ antibody inhibitor derived from mice that targets and inhibits mouse PD-1.</p>Color and Shape:Odour LiquidAnti-Mouse PD-1 Antibody (D265A) Antibody (RMP1-14)
<p>Anti-Mouse PD-1 Antibody (D265A) is an IgG2a, κ antibody inhibitor derived from mice, specifically targeting mouse PD-1.</p>Color and Shape:Odour LiquidOpamtistomig
CAS:<p>Opamtistomig is a humanized monoclonal antibody immunoglobulin (H-γ1-scFv-L-κ) dimer targeting human programmed death-ligand 1 (PD-L1), CD274, and tumor necrosis factor receptor superfamily member 9 (TNFRSF9). It is anticipated for use in research on various solid tumors and hematologic malignancies.</p>Color and Shape:LiquidTQB-2858
<p>TQB-2858 is a bifunctional fusion protein composed of an anti-PD-L1 monoclonal antibody fused with the extracellular domain of the TGF-β receptor. It exhibits high affinity for PD-L1, TGF-β1, and TGF-β3, and demonstrates a high target occupancy rate for PD-L1. TQB-2858 can be used in research on osteosarcoma and alveolar soft part sarcoma (ASPS).</p>Color and Shape:Odour LiquidPD-1/PD-L1-IN-49
<p>PD-1/PD-L1-IN-49 (compound 1c) is a potent inhibitor of PD-1/PD-L1 with an IC50 of 77 nM. This compound can activate Jurkat T cells and effectively block the PD-1/PD-L1 immune checkpoint.</p>Formula:C27H32N4O5Color and Shape:SolidMolecular weight:492.567AUNP-12
CAS:<p>AUNP-12, a new immune checkpoint modulator, is an inhibitor of the PD-1 pathway.</p>Formula:C142H226N40O48Purity:98%Color and Shape:SolidMolecular weight:3261.55Lon-TK
<p>Lon-TK is a glycolysis inhibitor of LTB, linked with a linker conjugate. LTB is an intelligent responsive prodrug, comprised of Lonidamine (Lon) and a PD-L1 inhibitor (BMS-1), which are connected through a thioketal linkage. It effectively inhibits glycolytic metabolism in tumor cells and blocks the PD-1/PD-L1 immune escape pathway. Lon-TK holds potential for use in photodynamic-enhanced immunotherapy research.</p>Formula:C24H28Cl2N2O3S2Color and Shape:SolidMolecular weight:527.53D5B
<p>D5B is an effective and selective PD-L1 inhibitor that has been modified with DBCO. It degrades PD-L1 in 4T1 and B16-F10 tumor cells with EC50 values of 5.4 μM and 6.2 μM, respectively. D5B can block the PD-L1/PD-1 interaction and exhibits antitumor activity.</p>Formula:C58H66N2O12Color and Shape:SolidMolecular weight:983.15PD-L1/VISTA-IN-2
<p>PD-L1/VISTA-IN-2 (Compound S8) is an orally active dual inhibitor targeting PD-L1 and VISTA, with an IC50 of 1.4 μM for PD-L1 and a KD of 2.1 μM for VISTA. This compound can activate the tumor immune microenvironment, exerting anticancer effects.</p>Formula:C22H22N2O3Color and Shape:SolidMolecular weight:362.42Ledostomig
CAS:<p>Ledostomig is an immunoglobulin (H-γ1-scFv-L-κ) dimer monoclonal antibody that targets human neurotensin receptor type 5 (NTS5) and programmed death-1 (PD-1). It shows potential for research in various cancer types.</p>Color and Shape:LiquidMoflerafusp alfa
CAS:<p>Moflerafusp alfa is a fusion protein that targets the human signal-regulatory protein alpha (SIRPα) variant V2 D1 domain and human programmed death-ligand 1 (PD-L1). It shows potential for research in various cancer treatments.</p>Color and Shape:LiquidZeluvalimab
CAS:<p>Zeluvalimab (AMG-404) is a monoclonal antibody designed to target the PD-1 receptor, and is utilized in cancer research [1].</p>Color and Shape:LiquidLTB
<p>LTB is a prodrug formed through the conjugation of the glycolysis inhibitor (Lonidamine) and the PD1/PDL1 blocker (BMS-1) via a thioketal bond. LTB can encapsulate the photosensitizer Chlorin e6 (Ce6), constructing a co-delivery photodynamic nanoplatfform through self-assembly (LTB-6 NPs).</p>Formula:C53H59Cl2N3O7S2Color and Shape:SolidMolecular weight:985.09Finotonlimab
<p>Finotonlimab (SCT-I10A), a humanized IgG PD-1 monoclonal antibody, shows potential in the research of solid tumors or lymphomas [1].</p>Color and Shape:Odour LiquidManelimab
CAS:<p>Manelimab is a monoclonal antibody that inhibits programmed death-ligand 1 ( PD-L1 ) [1] .</p>Color and Shape:Liquid2-Methylbiphenyl-oxadiazole-NH-Ph-NH-PEG3-C2-NH-Boc
<p>2-Methylbiphenyl-oxadiazole-NH-Ph-NH-PEG3-C2-NH-Boc is the PD-L1 ligand-linker polymer of AUTACPD-L1degrader-3. It can be utilized in the synthesis of AUTAC.</p>Formula:C35H45N5O6Color and Shape:SolidMolecular weight:631.76Lorigerlimab
CAS:<p>Lorigerlimab (MGD019) is a bispecific IgG4 DART that blocks PD-1/CTLA-4, enhancing T-cells for mCRPC research.</p>Color and Shape:Liquid2-Methylbiphenyl-oxadiazole-NH-Ph-CHO
CAS:<p>2-Methylbiphenyl-oxadiazole-NH-Ph-CHO functions as a PD-L1 ligand for AUTACPD-L1degrader-3. It is also applicable in the synthesis of AUTAC.</p>Formula:C22H17N3O2Color and Shape:SolidMolecular weight:355.39Izuralimab
CAS:<p>Izuralimab is a bispecific IgG1 antibody that targets both the inducible T-cell costimulator (ICOS/CD278) and PD-1 [1].</p>Color and Shape:LiquidCAY10678
CAS:<p>CAY10678 is an mPGES-1 inhibitor that inhibits PD-1.CAY10678 reduces collagen deposition and T-cell depletion, and may be used to study melanoma.CASHIPS</p>Formula:C23H34N4OPurity:99.66%Color and Shape:SolidMolecular weight:382.54Lodapolimab
CAS:<p>Lodapolimab (LY3300054) is an IgGλ anti- PD-1 monoclonal antibody [1] .</p>Color and Shape:LiquidPMT-O9-1A
<p>PMT-O9-1A is an effective PD-L1 degrader that reduces PD-L1 protein expression and exhibits cytotoxic properties. Additionally, PMT-O9-1A possesses anticancer activity.</p>Formula:C22H25ClN2O4Color and Shape:SolidMolecular weight:416.90Opucolimab
CAS:<p>Opucolimab is a human antibody targeting PD-L1, used in advanced solid tumor research and antibody-drug conjugate synthesis.</p>Color and Shape:LiquidBetifisolimab
CAS:<p>Betifisolimab (MSB-2311) is a humanized antibody targeting PD-L1 for solid tumors and blood cancer research.</p>Color and Shape:LiquidHX009
<p>HX009 is a bispecific antibody that targets PD1 and CD47, though its binding to CD47 is attenuated. HX009 functions by blocking PD1/CD47 and can be utilized in research related to non-Hodgkin lymphoma (NHL).</p>Color and Shape:Odour LiquidSudubrilimab
<p>Sudubrilimab (HS636) is an IgG1-κ monoclonal antibody targeting PDL1, fused with TGFBR2-ECD to block PD-1/PDL1 and TGF-β in tumors.</p>Color and Shape:Odour LiquidH-20
CAS:<p>H-20 is a PD-1 agonist that reduces the required dosage of morphine for analgesia. It can be used in studies related to chronic pain.</p>Formula:C44H64N10O15Color and Shape:SolidMolecular weight:973.037Pimivalimab
CAS:<p>Pimivalimab (JTX-4014), a PD-1 inhibitor, is utilized in solid tumor research [1].</p>Color and Shape:LiquidHuman membrane-bound PD-L1 polypeptide
CAS:<p>Human membrane-bound PD-L1 polypeptide serves as an antigen for inducing the production of PD-L1 antibodies [1].</p>Formula:C85H140N26O36SPurity:98%Color and Shape:SolidMolecular weight:2134.24Balstilimab
CAS:<p>Balstilimab (AGEN2034) is a fully human monoclonal IgG4 antibody against PD-1 [1] .</p>Color and Shape:LiquidIparomlimab
CAS:<p>Iparomlimab: anti-PD-1 IgG4κ antibody, targets PSB103 γ4/κ-chains, forms dimers, used in cancer research.</p>Color and Shape:LiquidPD-1/PD-L1-IN-9
CAS:<p>PD-1/PD-L1-IN-9, with an IC50 of 3.8 nM, is a potent and orally active inhibitor of the PD-1/PD-L1 interaction.</p>Formula:C22H24N2O2Purity:99.92%Color and Shape:SolidMolecular weight:348.44TPP-1 TFA
<p>TPP-1 TFA is a high-affinity PD-L1 inhibitor (KD=95nM) that boosts T-cell function to curb tumor growth.</p>Formula:C109H151F3N34O34S2Color and Shape:SolidMolecular weight:2602.69PD-1/PD-L1-IN-48
<p>PD-1/PD-L1-IN-48 (compound HD10) is an effective inhibitor of the PD-1/PD-L1 interaction, exhibiting an IC50 of 3.1 nM. It plays a vital role in cancer research.</p>Color and Shape:Odour SolidHuman PD-L1 inhibitor I
CAS:<p>Human PD-L1 inhibitor I, a peptide, blocks PD-L1/PD-1 interaction with 3.39 μM affinity.</p>Formula:C110H152N26O32Color and Shape:SolidMolecular weight:2350.576BMSpep-57
CAS:<p>BMSpep-57: Macrocyclic peptide, inhibits PD-1/PD-L1, IC50=7.68 nM, binds PD-L1 (Kd=19 nM/MST, 19.88 nM/SPR), boosts T cell IL-2 in PBMCs.</p>Formula:C89H126N24O19SColor and Shape:SolidMolecular weight:1868.2Human PD-L1 inhibitor II
CAS:<p>Human PD-L1 inhibitor II is a potent PD-L1 inhibitor with anti-cancer activity.</p>Formula:C103H151N25O30Color and Shape:SolidMolecular weight:2219.486Anti-Mouse PD-1 Antibody (RMP1-14)
<p>Anti-Mouse PD-1 Antibody (RMP1-14) is an IgG2a antibody inhibitor against mouse PD-1 and can block PD-1/PD-L1 signaling. High-Quality, Low-Cost!</p>Purity:14.68mg/ml - >95%Color and Shape:Odour LiquidPD-L1 inhibitory peptide
CAS:<p>PD-L1inhibitory peptide is an inhibitor peptide that targets the programmed cell death ligand 1 (PD-L1). By binding to PD-L1, it lifts immune suppression and restores the anti-tumor activity of T cells. PD-L1inhibitory peptide holds promise for use in tumor research.</p>Formula:C96H135N21O23SColor and Shape:SolidMolecular weight:1983.29Volrustomig
CAS:<p>Volrustomig is a bi-engineered fragment crystallizable (Fc) domain, a monovalent bispecific IgG1 monoclonal antibody targeting the key immune checkpoint receptors PD-1 and CTLA-4. It boosts T-cell activation and antitumor immunity, making it a promising immunotherapy for various cancers. Molecular weight: 146.77 kDa.</p>Color and Shape:LiquidHuman PD-L1 inhibitor IV
CAS:<p>PD-L1 inhibitor IV, a polypeptide, competitively blocks hPD-1 with a Kd of 1.38 μM, preventing hPD-1/hPD-L1 interaction.</p>Formula:C80H113N25O27Color and Shape:SolidMolecular weight:1856.932Human PD-L1 inhibitor III
CAS:<p>Human PD-L1 inhibitor III is a human PD-L1 inhibitor.</p>Formula:C97H155N29O29SColor and Shape:SolidMolecular weight:2223.54PD-L1-IN-5
<p>PD-L1-IN-5 (X22) is an orally active PD-L1 inhibitor with an IC50 of 785.6 nM, demonstrating antitumor activity in vivo.</p>PD-1/PD-L1-IN-39
<p>PD-1/PD-L1-IN-39 (X 14) is an orally active PD-1/PD-L1 inhibitor with an IC50 value of 15.73 nM. It exhibits strong binding affinity to human and mouse PD-L1, with KD values of 14.62 and 392 nM, respectively. PD-1/PD-L1-IN-39 also demonstrates antitumor activity.</p>Formula:C23H20ClFN2O3Molecular weight:426.11465PROTAC PD-L1 degrader-1
<p>PROTACPD-L1 degrader-1 is a CRBN-based PD-L1-PROTAC degrader with significant PD-L1 protein degradation capacity. It demonstrates strong PD-L1 degradation activity in 4T1 cells, with a DC50 of 0.609 μM. This compound is applicable to breast cancer research.</p>OPBP-1
<p>OPBP-1 is a D-peptide developed through phage display screening, molecular docking, and molecular dynamics simulations. It exhibits high stability, strong antitumor activity, and oral bioavailability. OPBP-1 selectively binds to the PD-L1 protein, significantly blocking the interaction between PD-1 and PD-L1, which helps restore and enhance T lymphocyte function while reducing the proportion of myeloid-derived suppressor cells (MDSCs), counteracting tumor-induced immune evasion. OPBP-1 is applicable for research in cancer immunotherapy.</p>Formula:C64H92N20O19SMolecular weight:1476.65683Sasanlimab
CAS:<p>Sasanlimab (PF-06801591), a humanized IgG4-κ antibody, selectively targets PD-1 and is primarily produced in Chinese Hamster Ovary (CHO) cells [1].</p>Purity:98%Color and Shape:LiquidCamrelizumab
CAS:<p>Camrelizumab (SHR-1210) is a human IgG4-κ monoclonal antibody with high affinity and directed against PD-1.Camrelizumab binds PD-1 with a binding affinity of up</p>Purity:95% - 98.6%Color and Shape:LiquidMolecular weight:143.7 kDaLipustobart
CAS:<p>Lipustobart is an IgG4-kappa humanized monoclonal antibody targeting PDCD1 (programmed cell death 1, PD1, PD-1, CD279), with immunostimulant and antineoplastic</p>Purity:98%Color and Shape:LiquidPidilizumab
CAS:<p>Pidilizumab (CT-011), a humanized IgG1κ anti-PD-1 monoclonal antibody, serves as a DLL1 antagonist with potential applications in researching hematologic</p>Purity:98%Color and Shape:LiquidNofazinlimab
CAS:<p>Nofazinlimab (CS1003) is a human anti-PD-1 IgG4 monoclonal antibody for the study of unresectable hepatocellular carcinoma (uHCC).</p>Purity:98.6% (SDS-PAGE); 99.7% (SEC-HPLC) - 98.6% (SDS-PAGE); 99.7% (SEC-HPLC)Color and Shape:LiquidLatikafusp
CAS:<p>Latikafusp (AMG 256) is a fusion protein that is a PD-1 blocker and IL-21R agonist with antitumor activity.</p>Purity:97.1% (SDS-PAGE); 97.4% (SEC-HPLC) - 97.1% (SDS-PAGE); 97.4% (SEC-HPLC)Color and Shape:LiquidPacmilimab
CAS:<p>Pacmilimab (CX-072) is a Probody immune checkpoint inhibitor targeting programmed death ligand 1 (PD-L1) with anti-tumor activity for the study of solid tumors.</p>Purity:98.8% (SDS-PAGE); 96.3% (SEC-HPLC) - 98.8% (SDS-PAGE); 96.3% (SEC-HPLC)Color and Shape:LiquidAcrixolimab
CAS:<p>Acrixolimab is a humanized IgG4-κ monoclonal antibody that selectively targets PD-1 [1] [2].</p>Purity:98%Color and Shape:LiquidProlgolimab
CAS:<p>Prolgolimab (BCD-100) is an anti-PD-1 antibody used in melanoma research.</p>Purity:>95%Color and Shape:LiquidRetifanlimab
CAS:<p>Retifanlimab (MGA-012) is a monoclonal antibody targeting programmed cell death protein 1 (PD-1). Retifanlimab is used in studies of Merkel cell carcinoma.</p>Purity:95% - 98.56% (SEC-HPLC)Color and Shape:LiquidAnti-Mouse PD-L1 Antibody (10F.9G2)
<p>Anti-Mouse PD-L1 Antibody (10F.9G2) is an IgG-class antibody against mouse PD-L1.</p>Purity:98.92% - >95% Determined by SDS-PAGEColor and Shape:Odour LiquidDanburstotug
CAS:<p>Danburstotug (IMC-001), an immunostimulant and antineoplastic [1], is a humanized IgG1-lambda monoclonal antibody targeting CD274 (PDL1, B7 homologue 1, B7H1).</p>Purity:98%Color and Shape:LiquidARB-272572 hydrochloride
CAS:<p>ARB-272572 hydrochloride is a PD-L1 inhibitor that inhibits PD-1/PD-L1 cell signaling by inducing PD-L1 protein homology interactions.</p>Formula:C32H36N6O4·xClHPurity:99.38%Color and Shape:SoildMolecular weight:568.68(Free base）IMMH 010 maleate
CAS:<p>IMMH 010 maleate (YPD-30 maleate) is a programmed cell death ligand 1 inhibitor used in the study of neurological disorders and advanced malignant solid tumors.</p>Formula:C36H36BrClN2O9Color and Shape:SoildMolecular weight:756.04LP23
<p>LP23, a non-arylmethylamine PD-1/PD-L1 inhibitor (IC 50: 16.7 nM), exhibits anti-tumor activity through the restoration of immune cell function in HepG2/Jurkat</p>Formula:C27H27N3O5SPurity:98%Color and Shape:SolidMolecular weight:505.59(D)-PPA 1 TFA
<p>(D)-PPA 1 TFA is a hydrolysis-resistant D-peptide antagonist and a potent PD-1/PD-L1 inhibitor, exhibiting an affinity for PD-1 of 0.51 μM and demonstrating</p>Formula:C72H99F3N20O23Purity:98%Color and Shape:SolidMolecular weight:1669.67PD-1/PD-L1-IN-31
<p>PD-1/PD-L1-IN-31 is a potent inhibitor of PD-1/PD-L1 (IC50=2.2 nM) that enhances IFN-γ secretion and activates the immune response of peripheral blood</p>Formula:C24H24ClFN2O3Purity:98%Color and Shape:SolidMolecular weight:442.91PD-1/PD-L1-IN-50
<p>Compound LG-12, known chemically as PD-1/PD-L1-IN-50, is an inhibitor of PD-1/PD-L1. It enhances the secretion of IFN-γ, promotes the activation of CD8+ T cells, and activates T cell-mediated anti-tumor immunity.</p>Color and Shape:Odour SolidPD-1/PD-L1-IN-51
<p>PD-1/PD-L1-IN-51 (Compound III-4) is an inhibitor of PD-1/PD-L1 (IC50: hPD-L1 at 2.9 nM). It binds directly to PD-L1, blocking the interaction between PD-1 and PD-L1, and enhancing the release of IFN-γ. Additionally, PD-1/PD-L1-IN-51 exhibits antitumor activity.</p>Color and Shape:Odour SolidPD-1/PD-L1-IN-32
<p>PD-1/PD-L1-IN-32 (compound A56) is a potent inhibitor of PD-1/PD-L1, displaying pronounced anticancer activity with an IC50 value of 2.4 nM.</p>Purity:98%Color and Shape:Odour SolidPD-1/PD-L1-IN-52
<p>PD-1/PD-L1-IN-52 (Compound Ⅲ-5) is an orally active inhibitor of PD-1/PD-L1 interaction, exhibiting an IC50 of 109.9 nM. It demonstrates antitumor activity in a C57BL/6 mouse model of MC38 colon carcinoma cells expressing human PD-1, achieving a tumor growth inhibition (TGI) rate of 49.6%.</p>Color and Shape:Odour SolidSotiburafusp alfa
CAS:<p>Sotiburafusp alfa is a humanized bispecific fusion protein comprising a VEGFR-1 extracellular domain fragment (129-228, 1-100 in the current sequence) connected</p>Purity:98%Color and Shape:SolidN-deacetylated BMS-202
CAS:<p>N-deacetylated BMS-202 is an inhibitor of PD-1/PD-L1 interaction with potential anticancer activity for cancer research.</p>Formula:C23H27N3O2Purity:98.13% - 98.13%Color and Shape:SolidMolecular weight:377.48BMS-8
CAS:<p>BMS-8 is a novel inhibitor of the PD-1/PD-L1 interaction (IC50: 7.2 μM) by binding directly to PD-L1 and inducing the formation of PD-L1 homodimers.</p>Formula:C27H28BrNO3Purity:98.88%Color and Shape:SolidMolecular weight:494.42BMS-1166
CAS:<p>BMS-1166 is a potent PD-1/PD-L1 interaction inhibitor.</p>Formula:C36H33ClN2O7Purity:99.22%Color and Shape:SolidMolecular weight:641.11Nivolumab
CAS:<p>Nivolumab is a monoclonal antibody, a humanized IgG4 antibody to PD-1. Nivolumab has antitumor activity. Cost-effective and quality-assured.</p>Purity:98% - 98%Color and Shape:LiquidMolecular weight:146 kDaPembrolizumab
CAS:<p>Pembrolizumab (MK-3475) is a humanized monoclonal antibody.Cost-effective and quality-assured.</p>Purity:95% - 99.70%Color and Shape:LiquidMolecular weight:149 kDaBMS-1001
CAS:<p>BMS-1001 is a potent inhibitor of PD-1/PD-L1 interaction(IC50 : 2.25 nM, in a homogenous time-resolved fluorescence binding assay).</p>Formula:C35H34N2O7Purity:98.43%Color and Shape:SolidMolecular weight:594.7Avelumab
CAS:<p>Avelumab is a fully human IgG1 anti-PD-L1 monoclonal antibody. Avelumab shows potential antibody-dependent cell-mediated cytotoxicity.</p>Purity:95% - 97.17% (SDS-PAGE)Color and Shape:LiquidMolecular weight:143.8 kDaARB-272572
CAS:<p>ARB-272572 is a PD-L1 signaling inhibitor that produces immunostimulatory activity in human primary cells.</p>Formula:C32H36N6O4Purity:97.36% - 98.07%Color and Shape:SolidMolecular weight:568.67Socazolimab
CAS:<p>Socazolimab (ZKAB001) is a monoclonal antibody targeting PD-L1 with antitumor activity, used in studies of recurrent or metastatic cervical cancer.</p>Purity:95%Color and Shape:LiquidEnvafolimab
CAS:<p>Envafolimab (ASC 22) is a humanized antibody targeting PD-L1, with anticancer activity, blocking the PD-L1 and PD-1 interaction.</p>Purity:95%Color and Shape:LiquidBMS-1166-N-piperidine-CO-N-piperazine dihydrochloride
CAS:<p>BMS-1166-N-piperidine-CO-N-piperazine dihydrochloride is a resorcinol di-Ph ether scaffold-based programmed cell death-1 (PD-1)/programmed cell death ligand 1 (</p>Formula:C41H45Cl3N4O5Purity:98.94%Color and Shape:SoildMolecular weight:780.18Ivonescimab
CAS:<p>Ivonescimab (AK112) is a PD-1/VEGF bispecific antibody with cancer immunotherapy and anti-angiogenic effects, NSCLC).</p>Purity:95% - 95%Color and Shape:LiquidAcasunlimab
CAS:<p>Acasunlimab (GEN1046) is a bsAb that targets PD-L1 and 4-1BB, boosting T/NK cells and blocking PD-1/PD-L1 in cancer research.</p>Color and Shape:LiquidReozalimab
CAS:<p>Reozalimab (LY3434172) is a bispecific monoclonal antibody targeting PD-1/PD-L1, antitumour and enhances T-cell activation in vitro.</p>Purity:95% - 95%Color and Shape:LiquidPeresolimab
CAS:<p>Peresolimab is a humanized antibody targeting PD-1, potentially stimulating immune inhibitory pathways for autoimmune disease research.</p>Purity:95% - 95%Color and Shape:LiquidVisugromab
CAS:<p>Visugromab (CTL-002) is a monoclonal antibody that targets and neutralises GDF-15.</p>Purity:95% - 95%Color and Shape:LiquidGilvetmab
CAS:<p>Gilvetmab is a caninized anti-PD-1 antibody approved for veterinary use, researched for stage I-III mast cell tumors and stage II-III melanoma in dogs.</p>Purity:95% - 95%Color and Shape:LiquidRulonilimab
CAS:<p>Rulonilimab, a human IgG1 monoclonal antibody, inhibits PD-1 to enhance immune response and exhibit anti-tumor effects.</p>Color and Shape:LiquidRosnilimab
CAS:<p>Rosnilimab is a PD-1 agonist that inhibits T cell proliferation and depletes T cells, enabling research into inflammatory diseases.</p>Purity:95% - 95%Color and Shape:Liquid
